Patents by Inventor Joel R. Huff
Joel R. Huff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5807841Abstract: Compounds of formula ##STR1## are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: April 8, 1997Date of Patent: September 15, 1998Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Joseph P. Vacca, Bruce D. Dorsey
-
Patent number: 5760054Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.Type: GrantFiled: October 1, 1996Date of Patent: June 2, 1998Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Hee-Yoon Lee, Jennie B. Nerenberg, Wayne J. Thompson, Ian M. Bell
-
Patent number: 5717097Abstract: Compounds of formula ##STR1## where A is usually carbonyl or --CH.sub.2 --, D is usually --CH.sub.2 --; R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: December 4, 1996Date of Patent: February 10, 1998Assignee: Merck & Co., Inc.Inventors: Joseph P. Vacca, Bruce D. Dorsey, James P. Guare, M. Katharine Holloway, Randall W. Hungate, Rhonda B. Levin, Joel R. Huff
-
Patent number: 5646148Abstract: Compounds of formula ##STR1## are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: March 29, 1995Date of Patent: July 8, 1997Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Joseph P. Vacca, Bruce D. Dorsey
-
Patent number: 5527819Abstract: Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: June 7, 1995Date of Patent: June 18, 1996Assignee: Merck & Co., Inc.Inventors: Theresa M. Williams, Terrence M. Ciccarone, Walfred S. Saari, John S. Wai, William J. Greenlee, Suresh K. Balani, Mark E. Goldman, Anthony D. Theoharides, deceased, Jacob M. Hoffman, Jr., William C. Lumma, Jr., Joel R. Huff, Clarence S. Rooney, Philip E. Sanderson
-
Patent number: 5502060Abstract: Oligopeptide analogs are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivitals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: October 25, 1994Date of Patent: March 26, 1996Assignee: Merck & Co., Inc.Inventors: Wayne J. Thompson, Arun K. Ghosh, Joel R. Huff, Hee Y. Lee
-
Patent number: 5502053Abstract: Compounds of formula ##STR1## are HIV protease inhibitors, and are synthesized via a novel route. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: August 23, 1994Date of Patent: March 26, 1996Assignee: Merck & Co., Inc.Inventors: Bruce D. Dorsey, Joel R. Huff, Susan F. Britcher
-
Patent number: 4923878Abstract: Compounds of formula I and its pharmaceutically acceptable salts are formulated with a pharmaceutical carrier for the treatment or prevention of neoplastic diesase states sensitive to such treatment in animals including humans ##STR1## wherein: A is an alkyl group having 1-6 carbons;X is oxygen, sulfur, or --NH--;R is hydrogen or an alkyl group having 1-6 carbons; andR.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, a halogen a C.sub.1-6 alkyl group, or C.sub.1-3 alkoxy.Type: GrantFiled: November 14, 1988Date of Patent: May 8, 1990Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Allen I. Oliff
-
Patent number: 4916223Abstract: Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective .alpha..sub.2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.Type: GrantFiled: February 6, 1989Date of Patent: April 10, 1990Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, Joel R. Huff, Susan J. DeSolms, Joseph P. Vacca, Jonathan M. Wiggins, Steven D. Young
-
Patent number: 4831035Abstract: Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective .alpha..sub.2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.Type: GrantFiled: July 27, 1987Date of Patent: May 16, 1989Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, Joel R. Huff, Susan J. deSolms, Joseph P. Vacca, Jonathan M. Wiggins, Steven D. Young
-
Patent number: 4824849Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, platelet aggregation inhibitors, antiobesity agents, and modifiers of gastrointestinal motility.Type: GrantFiled: August 28, 1987Date of Patent: April 25, 1989Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, Joel R. Huff, Joseph P. Vacca, Steven D. Young, Jane deSolms, James P. Guare, Jr.
-
Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
Patent number: 4710504Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, platelet aggregation inhibitors, antiobesity agents, and modifiers of gastrointestinal motility.Type: GrantFiled: April 4, 1986Date of Patent: December 1, 1987Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, Joel R. Huff, Joseph P. Vacca, Steven D. Young, Jane deSolms, James P. Guare, Jr. -
Patent number: 4690928Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.6 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, antidiabetics, antiobesity and platelet aggregation inhibitors.Type: GrantFiled: July 14, 1986Date of Patent: September 1, 1987Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Joseph P. Vacca, John J. Baldwin
-
Patent number: 4686226Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, antiobesity and platelet aggregation inhibitors and modifiers of gastrointestinal motility.Type: GrantFiled: September 3, 1985Date of Patent: August 11, 1987Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, John J. Baldwin, Yojiro Sakurai, Joseph P. Vacca, James P. Guare, Jr.
-
Patent number: 4505918Abstract: 4-[2-Pyridinylthio(oxy or amino)methyl]-1H-imidazoles and derivatives and acid addition salts thereof are selective central-adrenergic receptor agonists and thereby useful as antihypertensives.Type: GrantFiled: November 8, 1982Date of Patent: March 19, 1985Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Walfred S. Saari, John J. Baldwin
-
Patent number: 4506074Abstract: 2-[2-Pyridinyloxy(thio or amino)methyl]-1H-imidazoles and derivatives and acid addition salts thereof generally are selective .alpha..sub.2 -adrenergic receptor antagonists and .alpha..sub.1 -adrenergic receptor agonists and thereby useful as antidepressants and nasal decongestants.Type: GrantFiled: November 8, 1982Date of Patent: March 19, 1985Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Walfred S. Saari, John J. Baldwin
-
Patent number: 4381302Abstract: (6a.alpha.,10a.alpha.,11a.alpha.)-2-(2-pyridinyl)-1,3,4,6,6a,7,8,9,10,10a,1 1,11a-dodecahydro-2H-pyrazino[1,2-b]isoquinoline and derivatives or acid addition salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressant agents and for treating sedation caused by antihypertensive therapy.Type: GrantFiled: May 26, 1981Date of Patent: April 26, 1983Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Stella W. King, Walfred S. Saari
-
Patent number: 4376772Abstract: Piperazinyl-imidazo[1,2-a]pyrazines and their acid addition salts are selective .alpha..sub.2 -adrenergic receptor antagonists and are thereby useful for treating sedation caused by antihypertensive drug therapy.Type: GrantFiled: December 9, 1981Date of Patent: March 15, 1983Assignee: Merck & Co., Inc.Inventors: Walfred S. Saari, Joel R. Huff
-
Patent number: 4302455Abstract: 2-(4-Aminopiperidino)pyrazines are useful as analgesic and antidepressant agents. They are prepared by reductive amination of the corresponding 2-(4-oxopiperidino)pyrazines.Type: GrantFiled: April 14, 1980Date of Patent: November 24, 1981Assignee: Merck & Co., Inc.Inventors: Joel R. Huff, Stella W. King, Walfred S. Saari
-
Patent number: 4252816Abstract: Substituted tetrahydro-1H-1,4-diazepino[1,7-a]benzimidazoles of the formula: ##STR1## and pharmaceutically acceptable salts thereof having thereapeutic activity as analgesic agents.Type: GrantFiled: December 3, 1979Date of Patent: February 24, 1981Assignee: Merck & Co., Inc.Inventors: Walfred S. Saari, Joel R. Huff